Our technology is the first one to allow a highly controlled administration of radionuclides directly into the tumoral mass (or on the surgical bed following its resection).
It achieves the highest efficacy where it is needed, while at the same time minimizing the risk of unwanted side effects, both locally and in the entire patient’s body.
Administration device engineered to guarantee a precise delivery of the required dose of energy where it is needed, thus overcoming some disadvantages of external beam radiation therapy (EBRT).
The applications of this β-emitting radiotherapy platform vary from the intra-tumoral treatment of unresectable or metastatic tumors, to the treatment of surgical margins after tumor excision to avoid local recurrences.
Additional applications are in the prevention of complications following lung/liver biopsies, or other loco-regional treatments.